GlassScriptPhysician profile
Myrtho M Branch
NPI 1386675205
$5,050.77
in general payments reported to CMS, 2019-2025
25 companies · $1,554 in 2025
The $1,554 reported for 2025 was more than what 91% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $581 · 2020: $382 · 2021: $489 · 2022: $603 · 2023: $806 · 2024: $635 · 2025: $1,554.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,960 · Education: $34.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,960.45 |
| Education | $34.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $894.93 | 2019-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $684.63 | 2020-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $613.06 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| E.R. Squibb & Sons, L.L.C. | $409.97 | 2024-2025 | Cobenfy |
| Ironshore Pharmaceuticals INC. | $303.36 | 2019-2024 | Jornay Pm |
| Axsome Therapeutics, INC. | $232.76 | 2023-2025 | Auvelity |
| Abbvie INC. | $226.45 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $208.60 | 2022-2025 | Ingrezza |
| Tris Pharma INC | $203.94 | 2019-2025 | Dyanavel Xr, Onyda Xr |
| Corium, LLC | $193.20 | 2024-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $156.32 | 2021-2023 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $147.57 | 2019-2022 | |
| Neuronetics, INC. | $147.22 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $136.78 | 2022-2023 | Austedo |
| Alkermes, INC. | $117.46 | 2022-2025 | Lybalvi, Aristada |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $78.73 | 2025 | Jornay Pm |
| Sunovion Pharmaceuticals INC. | $75.66 | 2020-2021 | |
| Adlon Therapeutics L.P. | $40.34 | 2019 | |
| Idorsia Pharmaceuticals US INC | $39.85 | 2023-2025 | Quviviq, Quviviq |
| Neos Therapeutics, LP | $36.71 | 2019 | |
| Shire North American Group INC | $31.71 | 2019 | |
| Noven Therapeutics, LLC | $23.92 | 2025 | Xelstrym |
| Jazz Pharmaceuticals INC. | $16.68 | 2019 | |
| Bausch Health US, LLC | $16.16 | 2025 | Aplenzin |
| Alfasigma USA, INC. | $14.76 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Myrtho Branch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.